Biotechnology Value Fund's Ownership in Cidara Therapeutics

The filing discloses the ownership details of Biotechnology Value Fund, L.P. and its related entities in Cidara Therapeutics, Inc. As of October 17, 2025, Biotechnology Value Fund, L.P. owns approximately 2.3% of the outstanding shares, while Biotechnology Value Fund II, L.P. owns about 1.7%. Biotechnology Value Trading Fund OS LP owns less than 1%. The filing also indicates that BVF GP Holdings LLC may be deemed to beneficially own approximately 4.0% of the outstanding shares, and each of BVF Partners L.P., BVF Inc., and Mark N. Lampert may be deemed to beneficially own approximately 4.4% of the outstanding shares. The filing is an amendment to a previous Schedule 13G and is filed under Rule 13d-1(c).